ANRO

Conviction 100HealthcareScan · Mon, Aug 10, 2026

ANRO$28.22-1.57%

ResistanceSupportVol 14

Vol MA14 419.83K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Alto Neuroscience, Inc.PHARMACEUTICAL PREPARATIONSwww.altoneuroscience.com ↗

Price28.22

Change-1.57%

Gap+0.10%

Rel volume2.08×

Avg volume461.93K

Avg $ vol12.74M

SMA 2027.55

SMA 5024.89

SMA 20020.17

Price vs 50+13.40%

Price vs 200+39.92%

MA stackbullish

50/200 cross—

Supertrendup · 23.04

RSI (14)57

MACD hist-0.04

MACD cross—

Stoch %K / %D66 / 73

ADX (14)28

+DI / −DI15 / 9

RSI divergenceBearish

MACD divergenceBearish

ATR %+6.46%

ADR %6.61%

52w high28.67

52w low3.06

From 52w high-1.57%

Above 52w low+822.22%

New 52w highNo

SqueezeOn · 16d

Bollinger width10.19%

%B0.74

Donchian pos66.84%

Donchian high29.49

Donchian low25.66

AVWAP (52w high)28.30

vs AVWAP high-0.30%

AVWAP (52w low)13.62

vs AVWAP low+107.21%

OBV trendFlat

Chaikin MF (20)0.11

Today vs 20d2.08×

Avg vol (14d)419.82K

Avg vol (20d)461.93K

Avg $ vol (20d)12.74M

Market cap—

RS 3m (vs SPY)+13.41%

RS 6m (vs SPY)+89.08%

RS line new highNo

Trend template8/8

Technical rank82.5

1 week+3.48%

1 month+6.57%

3 months+16.32%

6 months+85.41%

1 year+822.22%

YTD+70.10%

P/E-15.90

P/B4.13

P/S—

P/FCF-19.42

EPS-2.19

Div yield—

ROE-25.98%

ROA-22.89%

Debt/Eq0.07

Current20.52

EV/EBITDA-11.51

Gross margin—

Net margin—

Rev growth—

EPS growth-2.94%

Price target35.71

Target upside24.60%

Analyst ratingBuy

Institutional77.47%

Ent. value758.05M

Revenue—

Net income-26.24M

Gross profit—

Free cash flow-51.79M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNYSE

Shares out35.09M

Employees68

ListedFri, Feb 2, 2024

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA+

Conviction100 / 100

Pattern quality—

Tech rank82.5 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance29.17

Support22.49

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ANRO

All disclosures →

No recent disclosed trades by Congress in ANRO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ANRO · 6 buys · 1 sell

Insider	Side	Shares	Value	Traded	Filed
Miller Andrew Craig Director · Stock Option (right to buy) · 2026-05-27	Grant	26K	$0	2026-05-27	2026-05-29
Etkin Amit PRESIDENT AND CEO · Common Stock · 2026-05-14	Gift	400K	$0	2026-05-14	2026-05-15
Cox Christopher Nixon Director · Stock Option (right to buy) · 2026-05-12	Grant	10.96K	$0	2026-05-12	2026-05-14
Sanchez Ramiro Director · Stock Option (right to buy) · 2026-05-12	Grant	10.96K	$0	2026-05-12	2026-05-14
Manji Husseini Director · Stock Option (right to buy) · 2026-05-12	Grant	10.96K	$0	2026-05-12	2026-05-14
Dreyfus Andrew Director · Stock Option (right to buy) · 2026-05-12	Grant	10.96K	$0	2026-05-12	2026-05-14
York Gwill Director · Stock Option (right to buy) · 2026-05-12	Grant	10.96K	$0	2026-05-12	2026-05-14

SEC filings

EDGAR filings in ANRO · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.